BidaskClub Downgrades AC Immune (NASDAQ:ACIU) to Buy

AC Immune (NASDAQ:ACIU) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday, BidAskClub reports.

ACIU has been the topic of several other reports. Zacks Investment Research lowered shares of AC Immune from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. TheStreet upgraded AC Immune from a “d” rating to a “c” rating in a research report on Monday, November 18th. Finally, ValuEngine lowered AC Immune from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. AC Immune has a consensus rating of “Hold” and an average price target of $9.83.

Shares of NASDAQ ACIU opened at $7.92 on Wednesday. The company has a current ratio of 22.08, a quick ratio of 22.09 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $6.33 and its 200 day moving average price is $5.55. AC Immune has a 52 week low of $3.25 and a 52 week high of $12.50. The stock has a market cap of $526.16 million, a price-to-earnings ratio of -9.66 and a beta of 0.32.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Wednesday, November 13th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.08. AC Immune had a net margin of 45.19% and a return on equity of 19.18%. The company had revenue of $33.90 million during the quarter, compared to analysts’ expectations of $31.50 million. As a group, research analysts expect that AC Immune will post 0.38 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of ACIU. Cubist Systematic Strategies LLC purchased a new stake in AC Immune during the 2nd quarter worth about $58,000. Tower Research Capital LLC TRC purchased a new position in AC Immune in the 3rd quarter valued at about $62,000. Appleton Partners Inc. MA purchased a new position in AC Immune in the 2nd quarter valued at about $85,000. JPMorgan Chase & Co. boosted its stake in shares of AC Immune by 20.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 18,162 shares of the company’s stock worth $99,000 after purchasing an additional 3,113 shares during the last quarter. Finally, Athanor Capital LP acquired a new stake in shares of AC Immune during the 2nd quarter worth about $234,000. 27.81% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Article: What is the significance of a dead cat bounce?

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.